



**Cosmetic
Supplies
USA, Inc.**

Material Safety Data Sheet

8810 Commodity Cir #20

Orlando, FL 32819-9066

877-926-7872 phone • 877-926-8742 fax

ATTENTION !

USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.

LIDOCAINE

Catalog Number: 1366002

Revision Date:

October 1, 2005

SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION

Common Name: Lidocaine

Manufacturer: U. S. Pharmacopeia

Responsible Party: Cosmetic Supplies USA, Inc.

Mailing Address: 8810 Commodity Cir #20
Orlando, FL 32819-9066
877-926-7872 phone • 877-926-8742 fax

Product Use: USP Reference Standards and Authentic Substances are used for chemical tests and assays in analytical, clinical, pharmaceutical, and research laboratories.

SECTION 2 - HAZARD INFORMATION

EMERGENCY OVERVIEW - Toxic.

Adverse Effects: Adverse effects may include numbness, burning, stinging or swelling of skin, drowsiness or excitement, nervousness, dizziness, blurred vision, tremors, convulsions, unconsciousness, and possible cardiac arrest. When taken orally, lidocaine may cause nausea, vomiting, or abdominal discomfort. Possible allergic reaction to material if inhaled, ingested, or in contact with skin.

Overdose Effects: Symptoms of overdose include low blood pressure; blurred or double vision; nausea or vomiting; ringing in ears; tremors or twitching; difficult breathing; increased sweating; change in heart rate with possible cardiac arrest; pale skin; vision or hearing disturbances; feeling hot, cold, or numb; confusion; convulsions; dizziness; drowsiness; trembling; anxiety or nervousness; headache; weakness; coma; and death..

Acute: Possible eye, skin, gastrointestinal, and/or respiratory tract irritation.

Chronic: Possible hypersensitization.

Medical Conditions Aggravated by Exposure: Hypersensitivity to material, respiratory depression, existing cardiac conditions, and impaired liver or kidney function.

Cross Sensitivity: Persons sensitive to other amide-type anesthetics, flecainide or tocainide may be sensitive to this material also.

Target Organs: Central nervous system and heart.

For additional information on toxicity, see Section 11.

SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS

LIDOCAINE

Catalog Number: 1366002

Revision Date:

October 1, 2005

Common Name: Lidocaine

Formula: C₁₄H₂₂N₂O

Synonym: Lignocaine

Chemical Name: Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-

CAS: 137-58-6

RTECS Number: AN7525000

Chemical Family: Aniline derivative

Therapeutic Category: Anesthetic (topical)

Composition: Pure Material

SECTION 4 - FIRST AID MEASURES

Inhalation: May cause irritation and numbness. Avoid inhalation. Remove to fresh air.

Eye: May cause irritation and numbness. Flush with copious quantities of water for 15 minutes.

Skin: May cause irritation and numbness. Avoid contact with skin. Absorption through intact skin is poor, but absorption may be increased through broken or inflamed skin. Flush with copious quantities of water.

Ingestion: May cause irritation, numbness, and toxicity. Avoid ingestion. Flush out mouth with water. This material is readily absorbed from the gastrointestinal tract.

General First Aid Procedures: Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen. Obtain medical attention.

Note to Physicians

Overdose Treatment: Overdose treatment is symptomatic and may consist of the following:

1. Administer activated charcoal or cathartics as soon as possible after ingestion.
 2. For circulatory depression, administer a vasopressor and intravenous fluids.
 3. For convulsions, consider slow intravenous administration of a diazepam or an ultra-short-acting barbiturate. Maintain caution in case of additive circulatory depression.
 4. A cardiac pacing wire may be necessary for heart block.
 5. For asystole, fluids, dopamine, intubation, epinephrine, atropine, and cardiac pacing may be needed.
- [USP DI and HSDB 2005]

SECTION 5 - FIREFIGHTING MEASURES

Extinguisher Media: Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.

Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders, it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

SECTION 6 - ACCIDENTAL RELEASE MEASURES

Spill Response: Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

SECTION 7 - HANDLING AND STORAGE

Handling: As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

LIDOCAINE

Catalog Number: 1366002

Revision Date:

October 1, 2005

Storage: Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

SECTION 8 - EXPOSURE CONTROL / PERSONAL PROTECTION

Engineering Controls: Engineering controls such as exhaust ventilation are recommended.

Respiratory Protection: Use a NIOSH-approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.

Gloves: Chemically compatible

Eye Protection: Safety goggles or glasses

Protective Clothing: Protect exposed skin.

Exposure Limits: n/f

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Properties as indicated on the MSDS are general and not necessarily specific to the USP Reference Standard Lot provided.

Appearance and Odor: White or slightly yellow crystalline powder; characteristic odor.

Odor Threshold: n/f

pH: n/f

Melting Range: 66 - 70° C

Boiling Point: 180 - 182° C @ 4 mm Hg

Flash Point: n/f

Autoignition Temperature: n/f

Evaporation Rate: n/f

Upper Flammability Limit: n/f

Lower Flammability Limit: n/f

Vapor Pressure: n/f

Vapor Density: n/f

Specific Gravity: n/f

Solubility in Water: Practically insoluble

Fat Solubility: n/f

Other Solubility: Very soluble in alcohol and in chloroform. Freely soluble in ether and in benzene. Dissolves in oils.

Partition Coefficient: n-octanol/water: n/f

Percent Volatile: n/f

Reactivity in Water: n/f

Explosive Properties: n/f

Oxidizing Properties: n/f

Formula: C₁₄H₂₂N₂O

Molecular Weight: 234.3

LIDOCAINE

Catalog Number: 1366002

Revision Date:

October 1, 2005

SECTION 10 - STABILITY AND REACTIVITY

Conditions to Avoid: n/f

Incompatibilities: Strong oxidizing agents and strong mineral acids.

Decomposition Products: When heated to decomposition, material emits toxic fumes of NO_x. Emits toxic fumes under fire conditions.

Stable? Yes **Hazardous Polymerization?** No

SECTION 11 - TOXICOLOGICAL PROPERTIES

Oral Rat: LD50: 317 mg/kg

Oral Mouse: LD50: 220 mg/kg

Other Toxicity Data: n/f

Irritancy Data: n/f

Corrosivity: n/f

Sensitization Data: n/f

Listed as a Carcinogen by: **NTP:** No **IARC:** No **OSHA:** No

Other Carcinogenicity Data: Metabolites of lidocaine have been shown to be carcinogenic in laboratory animals. [2005]

Mutagenicity Data: Lidocaine hydrochloride was not shown to be mutagenic in the salmonella/mammalian microsome test nor clastogenic in chromosome aberration assay with human lymphocytes and mouse micronucleus test.

Reproductive and Developmental Effects: Studies in animals have not shown that lidocaine causes adverse effects on the fetus. It is used as a local anesthetic during delivery.

SECTION 12 - ECOLOGICAL INFORMATION

Ecological Information: Low toxicity to aquatic organisms. Low potential for bioaccumulation.

SECTION 13 - DISPOSAL CONSIDERATIONS

Disposal: Dispose of waste in accordance with all applicable Federal, State, and local laws.

SECTION 14 - TRANSPORT INFORMATION

Shipping Name: n/f

Class: n/f

UN Number: n/f

Packing Group: n/f

Additional Transport Information: n/f

SECTION 15 - REGULATORY INFORMATION

U.S. Regulatory Information: n/f

International Regulatory Information: EINECS#: 205-302-8

SECTION 16 - OTHER INFORMATION

Revision: 01-Oct-05

Previous Revision Date: 08-Jan-02